| Previous Close | 70.42 |
| 1-Year Change | 19.42% |
| 6-Months Change | 13.29% |
| 3-Months Change | -8.51% |
| Moving Avg (50d) | 71.529 |
| Moving Avg (200d) | 66.23 |
| ESG Rating | - |
| Exchange | NASDAQ |
| Market Cap. | 13.6B |
| Beta (3-Years) | 0.52 |
| Revenue Growth (ttm) | 14.76% |
| Net Profit Margin (ttm) | 0.77% |
| Return On Assets (ttm) | 0.6% |
| EPS (ttm) | 0.2 |
| PE Ratio (ttm) | 352.1 |
| Dividend Yield | % |
Ask ChatGPT ?
This might take more than 30s in the first call...
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
| Sector: | Health Care |
| Industry: | Biotechnology |
| Country: | United States |
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity. Wikipedia